002755 奥赛康
已收盘 07-23 15:00:00
资讯
新帖
简况
奥赛康(002755)7月17日主力资金净买入124.84万元
证券之星 · 07-17
奥赛康(002755)7月17日主力资金净买入124.84万元
奥赛康(002755)7月15日主力资金净卖出932.65万元
证券之星 · 07-15
奥赛康(002755)7月15日主力资金净卖出932.65万元
奥赛康(002755.SZ)发预盈,预计上半年净利润6600万元至8500万元 同比扭亏为盈
智通财经 · 07-12
奥赛康(002755.SZ)发预盈,预计上半年净利润6600万元至8500万元 同比扭亏为盈
奥赛康最新公告:预计上半年净利润6600万元–8500万元 同比扭亏
证券之星 · 07-12
奥赛康最新公告:预计上半年净利润6600万元–8500万元 同比扭亏
7月12日奥赛康涨7.51%,华富健康文娱灵活配置混合A基金重仓该股
证券之星 · 07-12
7月12日奥赛康涨7.51%,华富健康文娱灵活配置混合A基金重仓该股
奥赛康(002755)7月9日主力资金净买入88.37万元
证券之星 · 07-09
奥赛康(002755)7月9日主力资金净买入88.37万元
奥赛康:截止2024年6月20日,公司股东人数是19,640户
证券之星 · 07-05
奥赛康:截止2024年6月20日,公司股东人数是19,640户
奥赛康最新公告:子公司注射用福沙匹坦双葡甲胺获得药品注册证书
证券之星 · 07-01
奥赛康最新公告:子公司注射用福沙匹坦双葡甲胺获得药品注册证书
奥赛康(002755.SZ):注射用福沙匹坦双葡甲胺获得药品注册证书
智通财经 · 07-01
奥赛康(002755.SZ):注射用福沙匹坦双葡甲胺获得药品注册证书
异动快报:奥赛康(002755)6月20日9点53分触及涨停板
证券之星 · 06-20
异动快报:奥赛康(002755)6月20日9点53分触及涨停板
国元证券:给予奥赛康买入评级
证券之星 · 06-03
国元证券:给予奥赛康买入评级
奥赛康(002755)5月22日主力资金净卖出9.66万元
证券之星 · 05-22
奥赛康(002755)5月22日主力资金净卖出9.66万元
奥赛康:ASK120067 片的评审工作在正常进行中,请您关注公司披露的定期报告及后续公告
证券之星 · 05-10
奥赛康:ASK120067 片的评审工作在正常进行中,请您关注公司披露的定期报告及后续公告
奥赛康(002755.SZ)收到注射用硫酸艾沙康唑药品注册证书
智通财经网 · 05-09
奥赛康(002755.SZ)收到注射用硫酸艾沙康唑药品注册证书
奥赛康最新公告:子公司注射用硫酸艾沙康唑获得药品注册证书
证券之星 · 05-09
奥赛康最新公告:子公司注射用硫酸艾沙康唑获得药品注册证书
奥赛康(002755)5月9日主力资金净卖出235.71万元
证券之星 · 05-09
奥赛康(002755)5月9日主力资金净卖出235.71万元
4月29日奥赛康涨10.00%,华富健康文娱灵活配置混合A基金重仓该股
证券之星 · 04-29
4月29日奥赛康涨10.00%,华富健康文娱灵活配置混合A基金重仓该股
4月29日奥赛康涨停分析:京津冀,幽门螺杆菌概念,创新药概念热股
证券之星 · 04-29
4月29日奥赛康涨停分析:京津冀,幽门螺杆菌概念,创新药概念热股
异动快报:奥赛康(002755)4月29日9点42分触及涨停板
证券之星 · 04-29
异动快报:奥赛康(002755)4月29日9点42分触及涨停板
奥赛康最新公告:一季度净利润3154.47万元 同比扭亏
证券之星 · 04-28
奥赛康最新公告:一季度净利润3154.47万元 同比扭亏
公司概况
公司名称:
北京奥赛康药业股份有限公司
所属行业:
医药制造业
上市日期:
2015-05-15
主营业务:
北京奥赛康药业股份有限公司主营业务是原料药及制剂的研发、生产、销售。主要产品为奥西康、奥丽瑞、奥罗沙、奥胜明、奥一明、奥维加、奥加明、潘美路、奥诺先、奥先达、奥锐安、奥维亚、奥哌柏、奥维丽、奥地西、奥名润、奥天成、奥达路、欧丽、奥替加、爱宣奥、奥佳泽、奥伏立、奥新泽、奥心怡、奥贝怡、奥法罗、奥立来、奥康宁。奥赛康药业先后获得南京市市长质量奖、江苏省质量奖、全球卓越绩效奖世界级和中国质量奖提名奖,并获评江苏省质量信用AAA级企业、中国化学制药质量信用AAA级企业、中国医药质量管理奖、中国化学制药行业创新型优秀企业品牌、全国医药行业药品质量诚信建设示范企业、全国医药行业质量管理小组活动优秀企业等。
发行价格:
7.49
{"stockData":{"symbol":"002755","market":"SZ","secType":"STK","nameCN":"奥赛康","latestPrice":9.97,"timestamp":1721718186000,"preClose":10.34,"halted":0,"volume":3004091,"delay":0,"floatShares":927999999,"shares":927999999,"eps":-0.0522,"marketStatus":"已收盘","marketStatusCode":5,"change":-0.37,"latestTime":"07-23 15:00:00","open":10.3,"high":10.41,"low":9.94,"amount":30374600,"amplitude":0.0455,"askPrice":9.97,"askSize":11,"bidPrice":9.96,"bidSize":178,"shortable":0,"etf":0,"ttmEps":-0.0522,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1721784600000},"adr":0,"adjPreClose":10.34,"symbolType":"stock","openAndCloseTimeList":[[1721698200000,1721705400000],[1721710800000,1721718000000]],"highLimit":11.37,"lowLimit":9.31,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":928160351,"pbRate":3.3,"roa":"--","roe":"1.09%","epsLYR":-0.16,"committee":0.657143,"marketValue":9254000000,"floatMarketCap":9254000000,"peRate":-190.996166,"changeRate":-0.0358,"turnoverRate":0.0032,"status":1},"requestUrl":"/m/hq/s/002755/wiki","defaultTab":"wiki","newsList":[{"id":"2452718649","title":"奥赛康(002755)7月17日主力资金净买入124.84万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2452718649","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2452718649?lang=zh_cn&edition=full","pubTime":"2024-07-17 15:20","pubTimestamp":1721200857,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月17日收盘,奥赛康报收于10.14元,上涨3.47%,换手率0.82%,成交量7.62万手,成交额7758.44万元。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071700026459.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2451601692","title":"奥赛康(002755)7月15日主力资金净卖出932.65万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2451601692","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2451601692?lang=zh_cn&edition=full","pubTime":"2024-07-15 15:24","pubTimestamp":1721028273,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月15日收盘,奥赛康报收于9.77元,下跌5.24%,换手率0.87%,成交量8.03万手,成交额8016.57万元。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071500013236.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002755","BK0239"],"gpt_icon":0},{"id":"2450300525","title":"奥赛康(002755.SZ)发预盈,预计上半年净利润6600万元至8500万元 同比扭亏为盈","url":"https://stock-news.laohu8.com/highlight/detail?id=2450300525","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450300525?lang=zh_cn&edition=full","pubTime":"2024-07-12 18:27","pubTimestamp":1720780034,"startTime":"0","endTime":"0","summary":"智通财经APP讯,奥赛康 发布2024年半年度业绩预告,预计上半年归属于上市公司股东的净利润6600万元至8500万元,同比扭亏为盈。业绩变动原因说明1、营业收入增加:公司抗感染类、慢性病类产品销售增速较快,公司营业收入实现同比增长,盈利能力进一步提升。公司部分新药已完成研发投入较大的关键性临床研发阶段,本报告期内相关项目无需继续进行大规模研发投入,因此研发费用同比减少。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1150176.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002755"],"gpt_icon":0},{"id":"2450530795","title":"奥赛康最新公告:预计上半年净利润6600万元–8500万元 同比扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2450530795","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450530795?lang=zh_cn&edition=full","pubTime":"2024-07-12 18:10","pubTimestamp":1720779026,"startTime":"0","endTime":"0","summary":"奥赛康公告,预计上半年净利润6600万元–8500万元,同比扭亏。公司抗感染类、慢性病类产品销售增速较快,公司营业收入实现同比增长,盈利能力进一步提升。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200040021.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755"],"gpt_icon":0},{"id":"2450194308","title":"7月12日奥赛康涨7.51%,华富健康文娱灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2450194308","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450194308?lang=zh_cn&edition=full","pubTime":"2024-07-12 16:18","pubTimestamp":1720772305,"startTime":"0","endTime":"0","summary":"证券之星消息,7月12日奥赛康涨7.51%,收盘报10.31元,换手率0.95%,成交量8.83万手,成交额9083.91万元。重仓奥赛康的前十大公募基金请见下表:该股最近90天内共有1家机构给出评级,买入评级1家。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为华富健康文娱灵活配置混合A。华富健康文娱灵活配置混合A目前规模为2.83亿元,最新净值0.9139,较上一交易日上涨0.56%,近一年下跌10.58%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071200030605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2450022093","title":"奥赛康(002755)7月9日主力资金净买入88.37万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450022093","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450022093?lang=zh_cn&edition=full","pubTime":"2024-07-09 15:23","pubTimestamp":1720509811,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年7月9日收盘,奥赛康报收于9.24元,下跌2.63%,换手率0.41%,成交量3.83万手,成交额3531.53万元。7月9日的资金流向数据方面,主力资金净流入88.37万元,占总成交额2.5%,游资资金净流出20.65万元,占总成交额0.58%,散户资金净流出67.72万元,占总成交额1.92%。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070900026940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2449255269","title":"奥赛康:截止2024年6月20日,公司股东人数是19,640户","url":"https://stock-news.laohu8.com/highlight/detail?id=2449255269","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449255269?lang=zh_cn&edition=full","pubTime":"2024-07-05 20:01","pubTimestamp":1720180869,"startTime":"0","endTime":"0","summary":"证券之星消息,奥赛康(002755)07月05日在投资者关系平台上答复投资者关心的问题。投资者:请问截止到2024年6月20日股东户数是多少?谢谢奥赛康董秘:您好,截止2024年6月20日,公司股东人数是19,640户。投资者:请问截止到2024年6月28日收盘公司在册股东户数是多少?奥赛康董秘:您好,截止2024年6月28日,公司股东人数是17,607户。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500043993.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002755","BK0239"],"gpt_icon":0},{"id":"2448047963","title":"奥赛康最新公告:子公司注射用福沙匹坦双葡甲胺获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448047963","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448047963?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:26","pubTimestamp":1719822403,"startTime":"0","endTime":"0","summary":"奥赛康公告,子公司注射用福沙匹坦双葡甲胺获得药品注册证书。该药品主要适用于预防初次和重复使用中、高度致吐性抗肿瘤化疗药物引起的急性和迟发性恶心和呕吐。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070100021144.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","002755","BK0239"],"gpt_icon":0},{"id":"2448696373","title":"奥赛康(002755.SZ):注射用福沙匹坦双葡甲胺获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2448696373","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2448696373?lang=zh_cn&edition=full","pubTime":"2024-07-01 16:21","pubTimestamp":1719822091,"startTime":"0","endTime":"0","summary":"智通财经APP讯,奥赛康(002755.SZ)发布公告,公司的全资子公司江苏奥赛康药业有限公司于近日收到国家药品监督管理局(“药监局”)核准签发的注射用福沙匹坦双葡甲胺《药品注册证书》。据悉,福沙匹坦是阿瑞匹坦的前体药,其止吐作用来自于阿瑞匹坦。福沙匹坦静脉给药后可在30分钟内转化为阿瑞匹坦,后者通过选择性阻断神经激肽-1(NK-1)受体,从而抑制化疗药物所致呕吐,主要适用于预防初次和重复使用中、高度致吐性抗肿瘤化疗药物引起的急性和迟发性恶心和呕吐。注射用福沙匹坦双葡甲胺由默克公司研发,于2008年在美国和欧洲上市,目前暂未进入中国。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1143539.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2444594231","title":"异动快报:奥赛康(002755)6月20日9点53分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2444594231","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444594231?lang=zh_cn&edition=full","pubTime":"2024-06-20 09:55","pubTimestamp":1718848531,"startTime":"0","endTime":"0","summary":"证券之星6月20日盘中消息,9点53分奥赛康触及涨停板。目前价格10.82,上涨9.96%。其所属行业化学制药目前上涨。领涨股为常山药业。该股为幽门螺杆菌概念,创新药,医药概念热股,当日幽门螺杆菌概念概念上涨1.33%,创新药概念上涨0.96%,医药概念上涨0.33%。6月19日的资金流向数据方面,主力资金净流出153.59万元,占总成交额7.24%,游资资金净流出25.18万元,占总成交额1.19%,散户资金净流入178.77万元,占总成交额8.43%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062000014849.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2440141102","title":"国元证券:给予奥赛康买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2440141102","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440141102?lang=zh_cn&edition=full","pubTime":"2024-06-03 08:35","pubTimestamp":1717374915,"startTime":"0","endTime":"0","summary":"国元证券股份有限公司马云涛,朱仕平近期对奥赛康进行研究并发布了研究报告《首次覆盖报告:集采利空渐见底,创新转型即将迎来收获》,本报告对奥赛康给出买入评级,当前股价为10.54元。首次覆盖,给予“买入”评级。最新盈利预测明细如下:该股最近90天内共有1家机构给出评级,买入评级1家;过去90天内机构目标均价为11.26。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060300000454.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","000728"],"gpt_icon":0},{"id":"2437768234","title":"奥赛康(002755)5月22日主力资金净卖出9.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2437768234","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437768234?lang=zh_cn&edition=full","pubTime":"2024-05-22 15:25","pubTimestamp":1716362759,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月22日收盘,奥赛康报收于10.82元,下跌2.79%,换手率0.57%,成交量5.25万手,成交额5728.62万元。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024052200022439.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0239","002755"],"gpt_icon":0},{"id":"2434834771","title":"奥赛康:ASK120067 片的评审工作在正常进行中,请您关注公司披露的定期报告及后续公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2434834771","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434834771?lang=zh_cn&edition=full","pubTime":"2024-05-10 19:01","pubTimestamp":1715338873,"startTime":"0","endTime":"0","summary":"证券之星消息,奥赛康05月10日在投资者关系平台上答复投资者关心的问题。投资者:ask120067是否需要发补奥赛康董秘:您好,ASK120067 片的评审工作在正常进行中,请您关注公司披露的定期报告及后续公告,谢谢。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051000039011.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0239","BK0028"],"gpt_icon":0},{"id":"2434960570","title":"奥赛康(002755.SZ)收到注射用硫酸艾沙康唑药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2434960570","media":"智通财经网","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434960570?lang=zh_cn&edition=full","pubTime":"2024-05-09 19:49","pubTimestamp":1715255381,"startTime":"0","endTime":"0","summary":"奥赛康(002755.SZ)发布公告,公司的全资子公司江苏奥赛康药业有限公司于近日...","market":"hk","thumbnail":"https://img.zhitongcaijing.com/astock/16.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/astock/16.jpg?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1119462.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2434095503","title":"奥赛康最新公告:子公司注射用硫酸艾沙康唑获得药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2434095503","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434095503?lang=zh_cn&edition=full","pubTime":"2024-05-09 19:21","pubTimestamp":1715253686,"startTime":"0","endTime":"0","summary":"奥赛康公告,子公司注射用硫酸艾沙康唑获得药品注册证书。该药品主要用于成人患者侵袭性曲霉病和侵袭性毛霉病的治疗。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900035077.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0028","BK0239"],"gpt_icon":0},{"id":"2434052232","title":"奥赛康(002755)5月9日主力资金净卖出235.71万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2434052232","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2434052232?lang=zh_cn&edition=full","pubTime":"2024-05-09 15:27","pubTimestamp":1715239651,"startTime":"0","endTime":"0","summary":"证券之星消息,截至2024年5月9日收盘,奥赛康报收于11.37元,下跌0.7%,换手率0.49%,成交量4.51万手,成交额5177.94万元。奥赛康主营业务:聚焦于消化、抗肿瘤、抗感染、慢性病等四大主要治疗领域的产品研发、生产、销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024050900022198.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755","BK0028","BK0239"],"gpt_icon":0},{"id":"2431838948","title":"4月29日奥赛康涨10.00%,华富健康文娱灵活配置混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431838948","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431838948?lang=zh_cn&edition=full","pubTime":"2024-04-29 16:38","pubTimestamp":1714379923,"startTime":"0","endTime":"0","summary":"证券之星消息,4月29日奥赛康涨10.00%创60日新高,收盘报10.78元,换手率0.74%,成交量6.84万手,成交额7322.33万元。根据2024基金Q1季报公募基金重仓股数据,重仓该股的公募基金共10家,其中持有数量最多的公募基金为华富健康文娱灵活配置混合A。华富健康文娱灵活配置混合A目前规模为2.83亿元,最新净值1.0392,较上一交易日上涨2.84%,近一年下跌12.08%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900017561.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002755","BK0028"],"gpt_icon":0},{"id":"2431300483","title":"4月29日奥赛康涨停分析:京津冀,幽门螺杆菌概念,创新药概念热股","url":"https://stock-news.laohu8.com/highlight/detail?id=2431300483","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431300483?lang=zh_cn&edition=full","pubTime":"2024-04-29 15:44","pubTimestamp":1714376642,"startTime":"0","endTime":"0","summary":"证券之星消息,奥赛康涨停收盘,收盘价10.78元。该股于9点42分涨停,未打开涨停,截止收盘封单资金为2685.09万元,占其流通市值0.27%。4月29日的资金流向数据方面,主力资金净流入1636.34万元,占总成交额22.35%,游资资金净流出724.09万元,占总成交额9.89%,散户资金净流出912.24万元,占总成交额12.46%。近5日资金流向一览见下表:该股为京津冀,幽门螺杆菌概念,创新药概念热股,当日京津冀概念上涨3.91%,幽门螺杆菌概念概念上涨3.37%,创新药概念上涨2.84%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900012210.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1161","06978","BK0028","002755","BK1574","BK0239"],"gpt_icon":0},{"id":"2431404407","title":"异动快报:奥赛康(002755)4月29日9点42分触及涨停板","url":"https://stock-news.laohu8.com/highlight/detail?id=2431404407","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2431404407?lang=zh_cn&edition=full","pubTime":"2024-04-29 09:45","pubTimestamp":1714355144,"startTime":"0","endTime":"0","summary":"证券之星4月29日盘中消息,9点42分奥赛康触及涨停板。目前价格10.78,上涨10.0%。其所属行业化学制药目前上涨。该股为创新药,幽门螺杆菌概念,医药概念热股,当日创新药概念上涨1.68%,幽门螺杆菌概念概念上涨1.57%,医药概念上涨1.31%。4月26日的资金流向数据方面,主力资金净流出39.31万元,占总成交额0.77%,游资资金净流出41.94万元,占总成交额0.82%,散户资金净流入81.25万元,占总成交额1.59%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042900003530.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0028","002755"],"gpt_icon":0},{"id":"2430056487","title":"奥赛康最新公告:一季度净利润3154.47万元 同比扭亏","url":"https://stock-news.laohu8.com/highlight/detail?id=2430056487","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2430056487?lang=zh_cn&edition=full","pubTime":"2024-04-28 19:50","pubTimestamp":1714305018,"startTime":"0","endTime":"0","summary":"奥赛康公布2024年一季度报告,报告期营业收入4.48亿元,同比增长32.47%;归属于上市公司股东的净利润3154.47万元,同比扭亏为盈;归属于上市公司股东的扣除非经常性损益的净利润2353.61万元;基本每股收益0.03元。以上内容由证券之星根据公开信息整理,由算法生成(网信算备310104345710301240019号),与本站立场无关,如数据存在问题请联系我们。本文为数据整理,不对您构成任何投资建议,投资有风险,请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024042800008472.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002755"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2015-05-15","address":"北京市丰台区南四环西路188号七区28号楼","stockEarnings":[{"period":"1week","weight":0.0173},{"period":"1month","weight":-0.001},{"period":"3month","weight":0.0528},{"period":"6month","weight":0.005},{"period":"1year","weight":0.2056},{"period":"ytd","weight":-0.0786}],"companyName":"北京奥赛康药业股份有限公司","boardCode":"AI0027","perCapita":"52714股","boardName":"医药制造业","registeredCapital":"92816万元","compareEarnings":[{"period":"1week","weight":-0.0205},{"period":"1month","weight":-0.0276},{"period":"3month","weight":-0.0425},{"period":"6month","weight":0.0032},{"period":"1year","weight":-0.0786},{"period":"ytd","weight":-0.02}],"survey":" 北京奥赛康药业股份有限公司主营业务是原料药及制剂的研发、生产、销售。主要产品为奥西康、奥丽瑞、奥罗沙、奥胜明、奥一明、奥维加、奥加明、潘美路、奥诺先、奥先达、奥锐安、奥维亚、奥哌柏、奥维丽、奥地西、奥名润、奥天成、奥达路、欧丽、奥替加、爱宣奥、奥佳泽、奥伏立、奥新泽、奥心怡、奥贝怡、奥法罗、奥立来、奥康宁。奥赛康药业先后获得南京市市长质量奖、江苏省质量奖、全球卓越绩效奖世界级和中国质量奖提名奖,并获评江苏省质量信用AAA级企业、中国化学制药质量信用AAA级企业、中国医药质量管理奖、中国化学制药行业创新型优秀企业品牌、全国医药行业药品质量诚信建设示范企业、全国医药行业质量管理小组活动优秀企业等。","serverTime":1721751651285,"listedPrice":7.49,"stockholders":"17607人(较上一季度减少10.35%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"奥赛康(002755)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供奥赛康(002755)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"奥赛康,002755,奥赛康股票,奥赛康股票老虎,奥赛康股票老虎国际,奥赛康行情,奥赛康股票行情,奥赛康股价,奥赛康股市,奥赛康股票价格,奥赛康股票交易,奥赛康股票购买,奥赛康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"奥赛康(002755)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供奥赛康(002755)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}